Lack of a relationship between plasma PCSK9 concentrations and hepatic lipoprotein kinetics in obese people

Translational Research

Volumn 158, Issue 5, 2011, Pages 302-306

  Sullivan, Shelby ^a   Fabbrini, Elisa ^a,b   Horton, Jay D ^c   Korenblat, Kevin ^a   Patterson, Bruce W ^a   Klein, Samuel ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KEXIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTEIN CONVERTASE SUBTILISN KEXIN 9; TRACER; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; BODY COMPOSITION; BODY FAT; BODY MASS; CLEARANCE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL;

EID: 80054696614     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2011.06.006     Document Type: Article

References (33)

1. J.R. Downs, M. Clearfield, and S. Weis Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS JAMA 279 1998 1615 1622 (Pubitemid 28248586)
2. G.N. Levine, J.F. Keaney, and J.A. Vita Cholesterol reduction in cardiovascular disease-clinical benefits and possible mechanisms N Engl J Med 332 1995 512 521
3. Lipid Research Clinics Program The lipid research clinics coronary primary prevention trial results: I. reduction in incidence of coronary heart disease JAMA 251 1984 351 364
4. V. Manninen, M.O. Elo, and M.H. Frick Lipid alterations and decline in the incidence of coronary heart disease in the helsinki heart study JAMA 260 1988 641 651
5. S.O. Olofsson, J. BorN, and B. Apolipoprotein a clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis 2005 Blackwell Science Ltd Oxford, UK
6. J.D. Horton, J.C. Cohen, and H.H. Hobbs PCSK9: a convertase that coordinates LDL catabolism J Lipid Res 50 Suppl 2009 S172 S177
7. M.S. Brown, and J.L. Goldstein A receptor-mediated pathway for cholesterol homeostasis Science 232 1986 34 47 (Pubitemid 16037973)
8. J.L. Goldstein, and M.S. Brown The LDL receptor Arterioscler Thromb Vasc Biol 29 2009 431 438
9. A. Zaid, A. Roubtsova, and R. Essalmani Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration Hepatology 48 2008 646 654
10. D. Allard, S. Amsellem, and M. Abifadel Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia Hum Mutat 26 2005 497
11. D. Cunningham, D.E. Danley, and K.F. Geoghegan Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia Nat Struct Mol Biol 14 2007 413 419 (Pubitemid 46685885)
12. J.D. Horton, J.C. Cohen, and H.H. Hobbs Molecular biology of PCSK9: its role in LDL metabolism Trends Biochem Sci 32 2007 71 77 (Pubitemid 46199197)
13. D. Lopez PCSK9: an enigmatic protease Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 1781 2008 184 191
14. J.C. Cohen, E. Boerwinkle, T.H. Mosley, and H.H. Hobbs Sequence variations in PCSK9, low LDL, and protection against coronary heart disease N Engl J Med 354 2006 1264 1272
15. Z. Zhao, Y. Tuakli-Wosornu, and T.A. Lagace Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote Am J Hum Genet 79 2006 514 523 (Pubitemid 44384260)
16. B. Herbert, D. Patel, and S.N. Waddington Increased secretion of lipoproteins in transgenic mice expressing human D374Y PCSK9 under physiological genetic control Arterioscler Thromb Vasc Biol 30 2010 1333 1339
17. G. Lambert, A.-L. Jarnoux, and T. Pineau Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor Endocrinology 147 2006 4985 4995 (Pubitemid 44402206)
18. S. Poirier, G. Mayer, and S. Benjannet The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2 J Biol Chem 283 2008 2363 2372
19. S.G. Lakoski, T.A. Lagace, J.C. Cohen, J.D. Horton, and H.H. Hobbs Genetic and metabolic determinants of plasma PCSK9 levels J Clin Endocrinol Metab 94 2009 2537 2543
20. E. Fabbrini, B.S. Mohammed, and F. Magkos Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease Gastroenterology 134 2008 424 431 (Pubitemid 351173050)
21. M.L. Selzer The Michigan alcoholism screening test: the quest for a new diagnostic instrument Am J Psychiatry 127 1971 1653 1658
22. T.N. Frimel, S. Deivanayagam, A. Bashir, R. O'Connor, and S. Klein Assessment of intrahepatic triglyceride content using magnetic resonance spectroscopy J Cardiometab Syndr 2 2007 136 138
23. F. Magkos, B.W. Patterson, and B. Mittendorfer Reproducibility of stable isotope-labeled tracer measures of VLDL-triglyceride and VLDL-apolipoprotein B-100 kinetics Journal of Lipid Research 48 2007 1204 1211 (Pubitemid 46708687)
24. B.W. Patterson, B. Mittendorfer, N. Elias, R. Satyanarayana, and S. Klein Use of stable isotopically labeled tracers to measure very low density lipoprotein-triglyceride turnover J Lipid Res 43 2002 223 233 (Pubitemid 34184009)
25. G. Lambert, N. Ancellin, and F. Charlton Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment Clin Chem 54 2008 1038 1045 (Pubitemid 351793411)
26. J. Mayne, A. Raymond, and A. Chaplin Plasma PCSK9 levels correlate with cholesterol in men but not in women Biochem Biophys Res Commun 361 2007 451 456 (Pubitemid 47193117)
27. Q. Cui, X. Ju, and T. Yang Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population Atherosclerosis 213 2010 632 636
28. Z. Zhao, Y. Tuakli-Wosornu, and T.A. Lagace Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote Am J Hum Genet 79 2006 514 523 (Pubitemid 44384260)
29. J.C. Cohen, E. Boerwinkle, T.H. Mosley Jr., and H.H. Hobbs Sequence variations in PCSK9, low LDL, and protection against coronary heart disease N Engl J Med 354 2006 1264 1272
30. I.K. Kotowski, A. Pertsemlidis, and A. Luke A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol Am J Hum Genet 78 2006 410 422 (Pubitemid 43291224)
31. A. Grefhorst, M.C. McNutt, T.A. Lagace, and J.D. Horton Plasma PCSK9 preferentially reduces liver LDL receptors in mice J Lipid Res 49 2008 1303 1311
32. A. Roubtsova, M.N. Munkonda, and Z. Awan Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue Arterioscler Thromb Vasc Biol 31 2011 785 791
33. F. Magkos, E. Fabbrini, and K. Korenblat Reproducibility of glucose, fatty acid and VLDL kinetics and multi-organ insulin sensitivity in obese subjects with non-alcoholic fatty liver disease Int J Obes (Lond) 2010 Dec 21 [Epub ahead of print]